Cargando…
PI3K/mTOR Pathway Inhibition: Opportunities in Oncology and Rare Genetic Diseases
The phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) signaling pathway has been implicated as a cancer target. Big pharma players and small companies have been developing small molecule inhibitors of PI3K and/or mTOR since the 1990s. Although four inhibitors have been approv...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6888641/ https://www.ncbi.nlm.nih.gov/pubmed/31752127 http://dx.doi.org/10.3390/ijms20225792 |